WO2011070084A1 - Milieu de culture cellulaire contenant des mogrosides utilisé pour cultiver des cellules souches - Google Patents
Milieu de culture cellulaire contenant des mogrosides utilisé pour cultiver des cellules souches Download PDFInfo
- Publication number
- WO2011070084A1 WO2011070084A1 PCT/EP2010/069204 EP2010069204W WO2011070084A1 WO 2011070084 A1 WO2011070084 A1 WO 2011070084A1 EP 2010069204 W EP2010069204 W EP 2010069204W WO 2011070084 A1 WO2011070084 A1 WO 2011070084A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- mogroside
- culture medium
- analogue
- cells
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 114
- 229930189775 mogroside Natural products 0.000 title claims abstract description 87
- 239000006143 cell culture medium Substances 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 83
- 239000001963 growth medium Substances 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 52
- 238000012258 culturing Methods 0.000 claims abstract description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 30
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 29
- 239000002609 medium Substances 0.000 claims description 26
- 210000004504 adult stem cell Anatomy 0.000 claims description 21
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 20
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 20
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 12
- 230000004069 differentiation Effects 0.000 claims description 11
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 8
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 8
- 230000001143 conditioned effect Effects 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- GHBNZZJYBXQAHG-KUVSNLSMSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GHBNZZJYBXQAHG-KUVSNLSMSA-N 0.000 claims description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 7
- -1 triterpenoid glycoside Chemical class 0.000 claims description 7
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 6
- 239000003797 essential amino acid Substances 0.000 claims description 6
- 235000020776 essential amino acid Nutrition 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 6
- 235000008777 kaempferol Nutrition 0.000 claims description 6
- TVJXHJAWHUMLLG-UHFFFAOYSA-N mogroside V Natural products CC(CCC(OC1OC(COC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(O)C3O)C(O)C(O)C1O)C(C)(C)O)C4CCC5(C)C6CC=C7C(CCC(OC8OC(COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C8O)C7(C)C)C6(C)C(O)CC45C TVJXHJAWHUMLLG-UHFFFAOYSA-N 0.000 claims description 6
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- WRPAFPPCKSYACJ-ZBYJYCAASA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8r,9r,10s,11r,13r,14s,17r)-17-[(5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydrox Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H](CCC(C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@@H]3[C@]2(C)CC1)C)C(C)(C)O)[C@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O WRPAFPPCKSYACJ-ZBYJYCAASA-N 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 239000012894 fetal calf serum Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 102000004338 Transferrin Human genes 0.000 claims description 4
- 108090000901 Transferrin Proteins 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229930191869 mogroside IV Natural products 0.000 claims description 4
- OKGRRPCHOJYNKX-UHFFFAOYSA-N mogroside IV A Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O OKGRRPCHOJYNKX-UHFFFAOYSA-N 0.000 claims description 4
- WRPAFPPCKSYACJ-UHFFFAOYSA-N mogroside IV E Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O WRPAFPPCKSYACJ-UHFFFAOYSA-N 0.000 claims description 4
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 125000003835 nucleoside group Chemical group 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 239000012581 transferrin Substances 0.000 claims description 4
- LTDANPHZAHSOBN-IPIJHGFVSA-N (2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[[(3S,8R,9R,10S,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LTDANPHZAHSOBN-IPIJHGFVSA-N 0.000 claims description 3
- XJIPREFALCDWRQ-UYQGGQRHSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-[(3r,6r)-2-hydroxy-6-[(3s,8s,9r,10r,11r,13r,14s,17r)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1h-cyclop Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJIPREFALCDWRQ-UYQGGQRHSA-N 0.000 claims description 3
- KYVIPFHNYCKOMQ-YMRJDYICSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[(3r,6r)-2-hydroxy-6-[(3s,8s,9r,10r,11r,13r,14s,17r)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYVIPFHNYCKOMQ-YMRJDYICSA-N 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- WVXIMWMLKSCVTD-JLRHFDOOSA-N Mogroside II-E Chemical compound O([C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WVXIMWMLKSCVTD-JLRHFDOOSA-N 0.000 claims description 3
- KYVIPFHNYCKOMQ-UHFFFAOYSA-N Mogroside III Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O KYVIPFHNYCKOMQ-UHFFFAOYSA-N 0.000 claims description 3
- 102100037369 Nidogen-1 Human genes 0.000 claims description 3
- 108010067787 Proteoglycans Proteins 0.000 claims description 3
- 102000016611 Proteoglycans Human genes 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 210000002469 basement membrane Anatomy 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 239000007758 minimum essential medium Substances 0.000 claims description 3
- 229930191873 mogroside II Natural products 0.000 claims description 3
- WVXIMWMLKSCVTD-UHFFFAOYSA-N mogroside II E Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC1OC(CO)C(O)C(O)C1O WVXIMWMLKSCVTD-UHFFFAOYSA-N 0.000 claims description 3
- 108010008217 nidogen Proteins 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- XJIPREFALCDWRQ-UHFFFAOYSA-N siamenoside I Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)OC2C(C(O)C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O XJIPREFALCDWRQ-UHFFFAOYSA-N 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 12
- 239000003636 conditioned culture medium Substances 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 7
- 230000001172 regenerating effect Effects 0.000 abstract description 6
- 238000011109 contamination Methods 0.000 abstract description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 29
- 239000000284 extract Substances 0.000 description 20
- 230000012010 growth Effects 0.000 description 17
- 210000001185 bone marrow Anatomy 0.000 description 10
- 210000003954 umbilical cord Anatomy 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000001654 germ layer Anatomy 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000007876 drug discovery Methods 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 241000219104 Cucurbitaceae Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000046949 human MSC Human genes 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 229930192771 11-oxomogroside Natural products 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 241001409321 Siraitia grosvenorii Species 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000000592 Artificial Cell Substances 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000427324 Glinus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001409305 Siraitia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical group 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
Definitions
- the present invention relates to a medium for growing stem cells, in particular, but not exclusively, primate stem cells, such as human mesenchymal stem cells.
- the invention further relates to methods of growing stem cells, to stem cells and differentiated cells provided by the methods of the invention and to use of same, for example, in therapy and drug discovery.
- Stem cells are characterized by their ability to (i) proliferate for long periods of time and (ii) differentiate into a diverse range of specialized cell types.
- the two broad types of mammalian stem cells are adult stem cells, which are found in adult tissues, and embryonic stem cells, which are derived from the inner cell mass of an early stage embryo known as a blastocyst.
- multipotency is differentiation of the cells into osteoblasts, adipocytes and chondrocytes.
- Pluripotent adult stem cells that is, stem cells that are able to differentiate into cells derived from any of the three primary germ layers, the ectoderm, endoderm and mesoderm, are rare.
- Adult stem cells have the potential to play an important role in therapy and regenerative medicine.
- adult stem cells have been successfully used in bone marrow transplants for the treatment of diseases such as leukemia and related bone/blood cancers.
- the use of adult stem cells is less controversial than the use of embryonic stem cells as the destruction of an embryo is not required.
- the risk of teratoma formation is greatly reduced when using adult stem cells when compared to the risk with embryonic stem cells.
- MSCs mesenchymal stem cells
- MSCs are found in the bone marrow, adipose tissue and the umbilical cord, and can differentiate into a number of cell types including osteoblasts, neuronal cells, chondrocytes, myocytes, adipocytes and beta- pancreatic islets cells.
- MSCs have potential for use in tissue repair.
- MSCs can take up and keep introduced genes, a phenomenon that could be exploited for the delivery of beneficial molecules to targeted locations.
- a further advantage of MSCs is that they can be frozen to preserve them, and upon thawing they appear to function normally.
- MSCs derived from the umbilical cord have been shown to have a low count per volume of the initial material and very low proliferative activity. It would be advantageous if large quantities of MSCs could be readily made available for use in therapy and other areas.
- MSCs can be propagated in culture for extended periods of time without losing their multipotency.
- Embryonic stem cells are pluripotent, that is, they are able to differentiate into cells derived from any of the three primary germ layers, the ectoderm, endoderm and mesoderm. For this reason, they are likely to play an important role in drug screening, functional genomics applications and therapies, such as regenerative medicine and replacement of damaged tissues.
- Embryonic stem cells were first derived from mouse embryos in 1981 . In 1998, a technique to isolate and grow primate embryonic stem cells derived from human blastocysts was first developed. Specific culture environments are required in order to maintain embryonic stem cells stem cells in an undifferentiated state. These requirements differ for human embryonic stem cells and mouse embryonic stem cells. If these requirements are not met, the embryonic stem cells will rapidly
- mouse embryonic stem cells are grown on a layer of gelatin in the presence of Leukemia Inhibitory Factor (LIF), which inhibits differentiation of mouse embryonic stem cells.
- LIF Leukemia Inhibitory Factor
- differentiation of human embryonic stem cells is inhibited by growing the human embryonic stem cells on a layer of feeder cells, known as a feeder layer.
- Typical feeder layers include animal cells, such as mouse embryonic fibroblasts, and human cells, such as human embryonic fibroblasts, human foreskin fibroblasts, human adult fallopian tubal epithelial cells, human fetal muscle and human fetal skin cells and adult skin fibroblast cell lines.
- the feeder cells provide an extracellular matrix and cellular contact for the maintenance of human embryonic stem cells in an undifferentiated state without losing their pluripotency.
- the feeder cells release factors and nutrients into the culture medium. These factors and nutrients may be used by the stem cells.
- pre-conditioned medium may be provided wherein the medium has firstly been conditioned by growing the feeder cells in the medium, following which the medium is harvested for subsequent stem cell culture.
- feeder cells pose a risk of contamination of human embryonic stem cells, in particular, contamination with non-human molecules, pathogens and other unidentified risk factors. This problem was discovered by scientists at the University of California, San Diego when non-human sialic acid in the growth media was found to compromise the potential uses of the embryonic stem cells in humans.
- bFGF Basic Fibroblast Growth Factor
- bFGF Basic Fibroblast Growth Factor
- the inventor has surprisingly developed a culture medium which facilitates the rapid growth of human adult stem cells, for example, mesenchymal stem cells (MSCs), without loss of their ability to differentiate.
- MSCs mesenchymal stem cells
- the culture medium of the present invention further facilitates the rapid growth of human embryonic stem cells in a substantially undifferentiated form in the absence of feeder cells or preconditioned medium.
- the culture medium of the invention may be used to provide improved methods for growing human embryonic stem cells wherein the risk of contamination is reduced.
- Adult and embryonic stem cells grown using the methods of the invention have potential for use in therapies, such as regenerative medicine, and in drug screening, particularly in cases where the absence of feeder cells is beneficial.
- a culture medium for growing stem cells comprising at least one mogroside and/or at least one analogue thereof.
- a method for growing stem cells comprising the step of:
- a composition comprising a culture medium comprising at least one mogroside and/or at least one analogue thereof and stem cells.
- a culture medium for growing stem cells comprising an extract of Luo Han Guo fruit.
- a method for growing stem cells comprising the step of:
- composition comprising a culture medium comprising an extract of Luo Han Guo fruit and stem cells.
- stem cells grown using the methods and/or medium of the present invention. The invention further extends to differentiated cells derived from said stem cells, and to the use of said stem cells and/or differentiated cells, for example, in therapy or drug discovery. Description of the Figures
- FIG 1 shows the growth index for bone marrow derived human Mesenchymal Stem Cells (MSCs) grown in the presence of basic Fibroblast Growth Factor (bFGF) or Luo Han Guo fruit extract (C53a);
- MSCs bone marrow derived human Mesenchymal Stem Cells
- bFGF basic Fibroblast Growth Factor
- C53a Luo Han Guo fruit extract
- Figure 2 shows the growth index for umbilical cord derived human MSCs grown in the presence of bFGF or Luo Han Guo fruit extract (C53a);
- Figure 3(a) shows the growth index for umbilical cord derived human MSCs grown in the presence of bFGF;
- Figure 3(b) shows the growth index for umbilical cord derived human MSCs grown in the presence of Luo Han Guo fruit extract (C53a).
- the present invention is directed to the use of at least one mogroside, and/or at least one analogue thereof, for culturing stem cells.
- mogrosides In the course of the inventor's work with mogrosides, he has unexpectedly discovered that the presence of one or more mogrosides in a suitable culture medium is sufficient to proliferate human adult stem cells without loss of their ability to differentiate.
- the inventor has further identified that the presence of one or more mogrosides in a suitable culture medium is sufficient to proliferate human embryonic stem cells in a substantially undifferentiated state through extended culture, for example, more than six months, in the absence of feeder cells and/or pre-conditioned medium.
- references to “a mogroside” or “at least one mogroside” includes a single mogroside as well as two or more different mogrosides in combination.
- reference to “an analogue” or “at least one analogue” includes a single analogue as well as two or more different analogues in combination.
- Reference to "at least one mogroside and/or at least one analogue thereof includes a single mogroside and two or more different analogues in combination, a single analogue and two or more different mogrosides in combination and two or more mogrosides with two or more analogues in combination.
- analogue as used herein is intended to refer to compounds having the same functional activity as a mogroside, though not necessarily to the same degree.
- the term “analogue” is intended to extend to derivatives and solvates of mogrosides, provided said derivative or solvate retains the appropriate functional activity, that is, to support the growth of undifferentiated stem cells, although not necessarily to the same degree as mogrosides.
- derivative as used herein includes chemical modification of the at least one mogroside.
- the term “without differentiation” or similar terms as used herein are intended to refer to cells that are substantially undifferentiated, that is cells that contain at least 20%, 40%, 60%, 80%, 85%, 90% or 95%
- feeder cell as used herein is intended to refer to cells that can be co-cultured with stem cells to inhibit differentiation of the stem cells.
- essentially free of feeder cells is intended to refer to cells that contain less than 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1 %, 0.5%, 0.1 % or 0.01 % feeder cells. In certain embodiments, the term refers to cells that contain less than 2% feeder cells.
- pre-conditioned refers to a medium which has been contacted with a first population of cells, for example feeder cells, prior to being combined with stem cells.
- the at least one mogroside and/or the at least one analogue thereof is added to a culture medium.
- the culture medium is substantially free of feeder cells, even more typically essentially free of feeder cells and preferably free of feeder cells.
- the presence of at least one mogroside and/or the at least one analogue thereof in the culture medium obviates the requirement for feeder cells as the at least one mogroside and/or the at least one analogue thereof inhibits differentiation of the stem cells whilst maintaining cell division. Accordingly, even after expansion a high proportion of the stem cells retain their ability to differentiate. This can be assessed by analysing morphological characteristics and phenotypic markers of the stem cells, as well as their ability to differentiate into the three germ layers for pluripotent stem cells.
- the culture medium is not pre-conditioned prior to combining the culture medium with the stem cells.
- the presence of at least one mogroside and/or the at least one analogue thereof in the culture medium obviates the requirement for the medium to be pre-conditioned. There is therefore no requirement for the medium to be brought into contact with other cell types, such as human or mouse feeder cells, before being combined with the stem cells.
- the absence of feeder cells in the culture medium and/or the absence of the use of pre-conditioned medium reduces the risk of contamination of the stem cells, for example by other species or other tissue types, thus increasing their potential for use in therapies such as regenerative medicine. It further allows more accurate results to be obtained when carrying out experiments using the stem cells, for example, in drug discovery.
- the at least one mogroside and/or the at least one analogue thereof acts as a growth stimulator.
- the addition of the at least one mogroside and/or the at least one analogue thereof to the culture medium has been shown in certain embodiments to increase the speed of growth of the stem cells whilst maintaining the cells' ability to differentiate.
- the stem cells expand up to one and a half times faster when cultured with at least one mogroside or analogue thereof compared to when cultured in the absence of at least one mogroside or analogue thereof, for example in the presence of feeder cells and/or in pre-conditioned medium.
- Cucurbitaceae family This fruit grows primarily in the mountains of Guilin, in the South-western Chinese province of Guangxi and is commonly known as Monk fruit.
- the fruit of Luo Han Guo has been cultivated in China for hundreds of years, primarily because of its sweet taste
- Extract of the Luo Han Guo plant is currently manufactured and marketed as a natural low-calorie sweetener, for example, PURELOTM.
- US Patent No. 5,41 1 ,755 describes a process for preparing a sweet juice from Luo Han Guo fruit.
- mogrosides There are no known toxicity issues relating to the use or consumption of mogrosides. These compounds have been used in contemporary Chinese medicine for centuries and have been in recorded human use since 1813. More recently, mogrosides have been shown to have beneficial effects in the treatment of diabetes, cancer and inflammation.
- a 90-day toxicity study carried out in canines showed no evidence of toxicity at an impressive dose of 3000 mg/kg bw/day.
- mogrosides are triterpene glycosides. Mogrosides possessing a triterpene backbone with two to six glucose units attached form mogrosides II to VI.
- the mogroside and/or the at least one analogue thereof is derived from a plant of the Cucurbitaceae species, in particular the fruit of the Cucurbitaceae species.
- the plant is Siraitia grosvenori Swingle (formerly Momoridca grosvenori Swingle).
- the fruit is Luo Han Guo.
- the at least one mogroside and/or the at least one analogue thereof is a triterpene glycoside or an analogue thereof.
- the at least one mogroside or analogue is selected from the group consisting of 20-hydroxy-1 1 -oxomogroside IA, 1 1 - oxomogroside IIE, ll-oxomogroside IA, mogroside IIE, mogroside III, mogroside IV, mogroside V, siamenoside I, triterpenoid glycoside V, neogroside, Kaempferol 7-a-i-rhamnopyranoside, Kaempferol 3,7- ⁇ - ⁇ - dirhamnopyranoside, 1 1 -oxomogroside III, ll-Dehydroxymogroside III, II- oxomogroside IV, mogroside II, mogroside VI, ll-oxo-mogroside and siamcroside-l, or an analogue thereof.
- the at least one mogroside or analogue thereof is selected from the group of compounds having the chemical formula shown in formula 1 below, or an analogue thereof.
- Formula 1 :
- the at least one mogroside and/or the at least one analogue thereof is added to the culture medium in an isolated form, for example, wherein the at least one mogroside or the analogue thereof has been isolated and purified from Luo Han Guo.
- the at least one mogroside and/or the at least one analogue thereof is added to the culture medium in the form of a crude extract of Luo Han Guo.
- the at least one mogroside and/or the at least one analogue thereof is added to the culture medium in the form of a natural sweetener or juice derived, for example, from Luo Han Guo, for example the juice obtained using the process described in US Patent No.
- the juice is dried and the at least one mogroside and/or the at least one analogue thereof is provided in a powder form.
- the at least one mogroside comprises a bacterially-transformed mogroside.
- the at least one mogroside comprises a mogroside in a synthetic form.
- the at least one mogroside and/or the at least one analogue thereof may be prepared by chemical synthesis techniques. This may be achieved by conventional techniques, for example as described in "Protective Groups in Organic Synthesis" by T W Greene and P G M Wuts, John Wiley and Sons lnc.(1991 ), and by P.J. Kocienski, in “Protecting Groups", Georg Thieme Verlag (1994).
- a mixture of mogrosides and/or analogues is used.
- the mogrosides and/or analogues are combined in set proportions by weight to achieve optimal stimulatory growth of the stem cells.
- the at least one mogroside and/or the at least one analogue thereof is added to the culture medium at a concentration of at least 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80 ng/ml. In alternative embodiments the at least one mogroside and/or at least one analogue thereof is added to the culture medium at a concentration of at least 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80 ng/ml. In alternative embodiments the at least one mogroside and/or at least one analogue thereof is added to the culture medium at a
- the at least one mogroside and/or the at least one analogue thereof is added to the culture medium at a concentration of at least 10 ng/ml.
- the at least one mogroside and/or the at least one analogue thereof is added to the culture medium at a concentration of at least 5 ⁇ / ⁇ . This concentration has been shown to be particularly effective in proliferating adult stem cells without differentiation.
- the culture medium comprises an extracellular matrix.
- the extracellular matrix supports the stem cells.
- the extracellular matrix comprises at least one of the group consisting of laminin, entactin, reconstituted basement membrane from Engelbreth-Holm-Swarm tumour cells, vitronectin, fibronectin or proteoglycan.
- a buffer such as an isotonic buffer
- proteins such as an isotonic buffer
- proteins such as an isotonic buffer
- proteins such as an isotonic buffer
- proteins such as an isotonic buffer
- proteins such as an isotonic buffer
- non-essential and/or essential amino acids such as fetal calf serum
- serum such as fetal calf serum
- reducing agent and beta-mercaptoethanol such as fetal calf serum
- the effective concentrations of such components may be determined by those of skill in the art of culturing cells.
- one or more additional factors such as fibroblast growth factor, for example, basic fibroblast growth factor (bFGF) may be added to the culture medium. These factors can be added to increase the rate of growth of the stem cells and to further inhibit differentiation of the stem cells.
- the culture medium is essentially free from fibroblast growth factor, for example, basic fibroblast growth factor.
- the culture medium is any suitable medium known in the art to which at least one mogroside or an analogue thereof has been added.
- the medium comprises a growth medium which supports growth of the stem cells.
- the medium is Minimum Essential Medium (MEM), which is a widely used synthetic cell culture media.
- MEM alpha is a parameter used synthetic cell culture media.
- the medium includes a nutrient serum which supports growth of the stem cells.
- the nutrient serum may replace nutrients that would otherwise be absent when a non pre-conditioned medium is used.
- fetal calf serum for example 10% fetal calf serum, is used.
- the medium is free from serum.
- the medium is pre-conditioned, for example by contact with feeder cells.
- non-conditioned medium may also be used as the presence of the at least one mogroside or analogue thereof obviates the requirement for a pre-conditioned medium.
- the stem cells comprise primate stem cells, preferably human stem cells. In alternative embodiments the stem cells comprise non-primate stem cells, for example, non-human stem cells. In certain embodiments the stem cells are embryonic stem cells. In alternative embodiments the stem cells are adult stem cells. In certain embodiments the stem cells comprise pluripotent stem cells, for example, human embryonic stem cells or human pluripotent adult stem cells. Typically the human embryonic stem cells are obtained from established human embryonic stem cells or from human blastocysts. In certain embodiments the stem cells comprise multipotent stem cells, for example, adult stem cells such as mesenchymal stem cells. In certain
- the stem cells are selected from the group consisting of, but not limited to, adipose derived adult stem cells, induced pluripotent stem cells derived from epithelial cells, haematopoietic stem cells, mammary stem cells, mesenchymal stem cells, endothelial stem cells, neural stem cells, olfactory adult stem cells, testicular cells and dental pulp derived stem cells.
- the stem cells are modified by in-vitro treatment or genetically altered, for example, by transfecting the stem cells with a suitable vector in order to provide a particular characteristic for a specific industrial application.
- stem cells provided by the method of the present invention are substantially undifferentiated cells.
- the stem cells comprise mainly undifferentiated pluripotent or multipotent stem cells.
- the stem cells comprise undifferentiated cells, in addition to differentiated and/or partially differentiated cells.
- the stem cells consist of undifferentiated cells.
- the pluripotent stem cells are capable of proliferating in-vitro whilst maintaining the potential to differentiate into derivatives of the three germ layers.
- the multipotent stem cells are capable of proliferating in-vitro whilst maintaining the potential to differentiate into cells of a closely related family of cells. Typically all the stem cells are derived from the same stem cells and therefore have the same genotype.
- the stem cells comprise mixed populations of different cell lines.
- the stem cells are differentiated into different cell types.
- the method of the present invention therefore further includes the step of differentiating the cells to produce different cells types, for example cells of the three germ layers or cells of a closely related family of cells. Typically the method may be carried out in vivo or in-vitro.
- differentiated cells can be obtained wherein 95% or more of the cells represent the same tissue type or germ layer, for example, cardiomyocytes, mesenchymal cells, neural cells, hepatocytes or osteoblasts.
- the present invention further extends to the use of the stem cells proliferated by the method of the present invention, for example, in therapy and tissue replacement, drug screening and development, analysis of mammalian development, analysis of pluripotency or multipotency, differentiation and cell proliferation, analysis of signalling pathways and analysis of genetics.
- a differentiated or multipotency for example, in therapy and tissue replacement, drug screening and development, analysis of mammalian development, analysis of pluripotency or multipotency, differentiation and cell proliferation, analysis of signalling pathways and analysis of genetics.
- undifferentiated stem cell of the invention may be transplanted into a human or non-human animal to treat a disease, such as a degenerative neurological disorder.
- said use includes a method of screening to identify an agent that affects stem cell function.
- the method includes incubating the agent and at least one stem cell cultured using the method of the present invention under conditions sufficient to allow the agent and the at least one stem cell to interact.
- the agent is allowed to interact with the at least one stem cell in the presence of the at least one mogroside and/or the at least one analogue thereof.
- the at least one mogroside and/or the at least one analogue thereof is not present when the agent is allowed to interact with the at least one stem cell.
- the method includes the step of determining the effect of the agent on the function of the at least one stem cell.
- the function that may be affected, for example inhibited or stimulated, by the agent includes cell
- MSCs Mesenchymal Stem Cells
- MSCs Luo Han Guo fruit extract derived using the process described in US Patent No. 5,41 1 ,755 on human Mesenchymal Stem Cells (MSCs) growth was examined using MSCs derived from bone marrow (BM) and the umbilical cord (UC). One sample was obtained from bone marrow and two samples were obtained from the umbilical cord. MSCs were seeded in 6 well plates at the indicated passage at 250 cells/cm 2 and cultured under the following conditions:
- Figure 1 shows the results obtained for MSCs derived from bone marrow.
- Figures 2 and 3 show the results obtained for the two MSCs samples derived from the umbilical cord.
- Figure 1 shows that Luo Han Guo fruit extract enhanced the growth of MSCs derived from bone marrow. Increased growth was observed for cells cultured with Luo Han Guo fruit extract when compared to the control or to cells cultured with bFGF. The best results were obtained using Luo Han Guo fruit extract at a range of 5 g/ml. However, the proliferative capacity of the MSCs derived from bone marrow was low under all culture conditions. It is hypothesised that the low proliferative capacity was due to the MSCs derived from bone marrow being seeded at the 6 th passage.
- Figures 2 and 3 demonstrate enhanced support and growth of MSCs derived from the umbilical cord cultured in the presence of Luo Han Guo fruit extract when compared to control cultures (no Luo Han Guo fruit extract). In some cases, the results obtained with Luo Han Guo fruit extract were better than those observed with bFGF (see Figure 2, 7 th passage). The best results were obtained using Luo Han Guo fruit extract at a range of 5 g/ml. These results demonstrate that Luo Han Guo fruit extract supports MSCs growth and expansion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne un milieu de culture permettant de cultiver des cellules souches, ledit milieu de culture comprenant au moins un mogroside et/ou au moins un de ses analogues. L'invention concerne également des procédés permettant de cultiver des cellules souches, comprenant l'étape consistant à cultiver les cellules souches en présence d'au moins un mogroside et/ou d'au moins un de ses analogues. La présence desdits mogrosides et/ou de leurs analogues permet de s'affranchir du besoin de cellules nourricières et/ou de milieu préconditionné, tout en permettant aux cellules souches de proliférer pendant de longues périodes sans perte de leur aptitude à se différencier. Les cellules cultivées au moyen des procédés de la présente invention présentent un potentiel d'utilisation accru en thérapeutique et en médecine régénérative dans la mesure où le risque de contamination des cellules souches est réduit.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE20090931 | 2009-12-11 | ||
IE2009/0931 | 2009-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011070084A1 true WO2011070084A1 (fr) | 2011-06-16 |
Family
ID=43662178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/069204 WO2011070084A1 (fr) | 2009-12-11 | 2010-12-08 | Milieu de culture cellulaire contenant des mogrosides utilisé pour cultiver des cellules souches |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011070084A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019004905A (ja) * | 2018-09-10 | 2019-01-17 | アナリティコン ディスカバリー ゲーエムベーハー | 甘味料または甘味増強剤として使用される新規なトリペルテングリコシド |
CN114774353A (zh) * | 2022-03-31 | 2022-07-22 | 巴马奥比特生命科技研究有限公司 | 一种干细胞培养基 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411755A (en) | 1993-02-16 | 1995-05-02 | The Procter & Gamble Company | Process and composition for sweet juice from cucurbitaceae fruit |
WO2006017370A2 (fr) | 2004-07-13 | 2006-02-16 | Geron Corporation | Milieu destine a la croissance de cellules souches embryonnaires humaines |
-
2010
- 2010-12-08 WO PCT/EP2010/069204 patent/WO2011070084A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411755A (en) | 1993-02-16 | 1995-05-02 | The Procter & Gamble Company | Process and composition for sweet juice from cucurbitaceae fruit |
WO2006017370A2 (fr) | 2004-07-13 | 2006-02-16 | Geron Corporation | Milieu destine a la croissance de cellules souches embryonnaires humaines |
Non-Patent Citations (7)
Title |
---|
ANONYMOUS: "Siraitia grosvenorii", WIKIPEDIA THE FREE ENCYCLOPEDIA, 6 February 2006 (2006-02-06), XP002628425, Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Siraitia_grosvenorii> [retrieved on 20110316] * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; March 2009 (2009-03-01), SHI AI-WU ET AL: "Ginsenoside Rg1 promotes endothelial progenitor cell migration and proliferation.", XP002628424, Database accession no. NLM19262553 * |
P.J. KOCIENSKI: "Protecting Groups", 1994, GEORG THIEME VERLAG |
SHI ET AL., ACTA PHARMACOLOGICA SINICA, vol. 30, no. 3, March 2009 (2009-03-01), pages 299 - 306, ISSN: 1745-7254 * |
T W GREENE; P G M WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY AND SONS INC. |
TAKASAKI MIDORI ET AL: "Anticarcinogenic activity of natural sweeteners, cucurbitane glycosides, from Momordica grosvenori.", CANCER LETTERS, vol. 198, no. 1, 30 July 2003 (2003-07-30), pages 37 - 42, XP002628426, ISSN: 0304-3835 * |
ZHOU YING ET AL: "Insulin secretion stimulating effects of mogroside V and fruit extract of Luo Han Kuo (Siraitia grosvenori Swingle) fruit extract", YAOXUE XUEBAO, 2009, pages 10PP, XP002628423, Retrieved from the Internet <URL:http://www.yxxb.com.cn:8080/yxxb_en/fileup/HTML/article_19215.htm> [retrieved on 20110316] * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019004905A (ja) * | 2018-09-10 | 2019-01-17 | アナリティコン ディスカバリー ゲーエムベーハー | 甘味料または甘味増強剤として使用される新規なトリペルテングリコシド |
CN114774353A (zh) * | 2022-03-31 | 2022-07-22 | 巴马奥比特生命科技研究有限公司 | 一种干细胞培养基 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Piedrahita et al. | Influence of feeder layer type on the efficiency of isolation of porcine embryo-derived cell lines | |
KR101443478B1 (ko) | 간엽계 줄기 세포를 포함한 세포 제제 및 그의 제조 방법 | |
LU502505B1 (en) | Immortalized yak rumen epithelial cell line and construction method thereof | |
AU2013221839B2 (en) | Feeder-free method for culture of bovine and porcine spermatogonial stem cells | |
CN102634482B (zh) | 一种间充质干细胞的无血清完全培养基 | |
CN101688177A (zh) | 来自贴壁胎盘干细胞的肝细胞和软骨细胞;以及cd34+、cd45-胎盘干细胞富集的细胞群 | |
KR102128224B1 (ko) | 향상된 산후 부착형 세포 및 그의 제조 방법 | |
KR20120008223A (ko) | 양막유래 중간엽 줄기세포 배양을 위한 배지조성물 및 이를 이용한 양막유래 중간엽 줄기세포의 배양방법 | |
AU2013403888B2 (en) | Method for differentiating pluripotent stem cell induced from mesenchymal stem cell into chondrocyte | |
CN104830763B (zh) | Y-27632在间充质干细胞培养中的应用及间充质干细胞的培养方法 | |
CN102899288B (zh) | 一种人胰岛来源的胰腺干细胞系的构建及向胰岛素分泌细胞分化的方法 | |
CN114480273A (zh) | 用于获得间充质干细胞及其外泌体的培养基及其制备方法 | |
CN108504625A (zh) | 一种小鼠成纤维细胞及其用途 | |
Mathis et al. | Biochemical characteristics of hyperplastic rat bile ductular epithelial cells cultured “on top” and “inside” different extracellular matrix substitutes | |
CN106929470A (zh) | 一种用于间充质干细胞体外培养和扩增的无血清培养基 | |
US20120052577A1 (en) | Culture system for stem cell propagation and neural and oligodendrocyte specification | |
JP2003535585A (ja) | 哺乳動物の配偶子および胚の培養基サプリメント、およびその使用法 | |
KR20060032958A (ko) | 전구 세포의 분리 및 증식 | |
CN111484970A (zh) | 一种低蛋白含量的无血清无饲养层胚胎与多能干细胞培养基 | |
WO2011070084A1 (fr) | Milieu de culture cellulaire contenant des mogrosides utilisé pour cultiver des cellules souches | |
RU2012107674A (ru) | Биотрансплантат для восстановления объема костной ткани при дегенеративных заболеваниях и травматических повреждениях костей и способ его получения | |
KR101656761B1 (ko) | 다능성 줄기 세포 및 심근 세포 이외의 분화성 세포에 대해 세포사멸을 유도하는 방법 | |
JP2007000077A (ja) | 付着性動物細胞の無血清培養方法及び付着性動物細胞の無血清培養用培地 | |
KR101523141B1 (ko) | 개과 동물 복제용 핵 공여 세포 배양용 배지 및 이의 이용 | |
CN102206609A (zh) | 一种卵巢来源雌性生殖干细胞的分离培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10790417 Country of ref document: EP Kind code of ref document: A1 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10790417 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10790417 Country of ref document: EP Kind code of ref document: A1 |